{"id":29919,"date":"2025-01-07T11:23:28","date_gmt":"2025-01-07T10:23:28","guid":{"rendered":"https:\/\/ggba.swiss\/vanarix-secures-fda-orphan-drug-designation-for-its-cartibeads\/"},"modified":"2025-01-07T11:30:48","modified_gmt":"2025-01-07T10:30:48","slug":"vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/","title":{"rendered":"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA pour ses Cartibeads"},"content":{"rendered":"\n<p>Fond\u00e9e en 2018, <a href=\"https:\/\/www.vanarix-cartilage-regeneration.ch\/\">Vanarix<\/a> r\u00e9alise des avanc\u00e9es significatives dans le domaine de la m\u00e9decine r\u00e9g\u00e9n\u00e9rative gr\u00e2ce \u00e0 sa technologie innovante Cartibeads. Ces mini-implants de cartilage issus de la bio-ing\u00e9nierie utilisent des cellules de cartilage de donneurs pour r\u00e9parer les l\u00e9sions du cartilage articulaire, r\u00e9pondant ainsi \u00e0 un besoin m\u00e9dical critique non satisfait. Les Cartibeads sont disponibles sous deux formes : autologue, d\u00e9riv\u00e9e des propres cellules du patient, et allog\u00e9nique, utilisant des cellules du donneur. Ces derni\u00e8res \u00e9liminent les probl\u00e8mes de compatibilit\u00e9 entre le donneur et le receveur tout en minimisant les risques de rejet.<\/p>\n\n\n\n<p>Les implants produisent un cartilage hyalin de haute qualit\u00e9, ce qui constitue une nette am\u00e9lioration par rapport aux solutions existantes qui produisent g\u00e9n\u00e9ralement du fibrocartilage. Bien que l&rsquo;accent soit actuellement mis sur le traitement du genou, Vanarix envisage des applications plus larges pour d&rsquo;autres articulations, offrant ainsi de l&rsquo;espoir \u00e0 des millions de personnes souffrant de l\u00e9sions du cartilage et d&rsquo;arthrose dans le monde entier.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Des r\u00e9sultats cliniques prometteurs et des projets d&rsquo;avenir<\/h4>\n\n\n\n<p>Le statut <a href=\"https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/designating-orphan-product-drugs-and-biological-products\">Orphan Drug<\/a> accord\u00e9 par la FDA aux Cartibeads pour le traitement de l&rsquo;ost\u00e9ochondrite diss\u00e9quante repr\u00e9sente un grand pas en avant pour Vanarix. Cette d\u00e9signation offre plusieurs avantages, notamment des cr\u00e9dits d&rsquo;imp\u00f4t pour les d\u00e9penses li\u00e9es aux essais cliniques, l&rsquo;exclusivit\u00e9 du march\u00e9 apr\u00e8s approbation, l&rsquo;exon\u00e9ration des frais de dossier et l&rsquo;acc\u00e8s \u00e0 des subsides. Ces incitations r\u00e9duisent la charge financi\u00e8re et r\u00e9glementaire, acc\u00e9l\u00e9rant ainsi le d\u00e9veloppement de traitements pour les maladies rares.<\/p>\n\n\n\n<p>Vanarix a d\u00e9j\u00e0 d\u00e9montr\u00e9 le potentiel de ses Cartibeads allog\u00e9niques lors d&rsquo;essais cliniques de phase I\/IIa, les patients reprenant une activit\u00e9 intensive dans le mois suivant le traitement. L&rsquo;entreprise vise maintenant \u00e0 augmenter la production pour traiter 200 patients au cours des essais de phase 2 et de phase 3, avec l&rsquo;objectif d&rsquo;achever le projet d&rsquo;ici 2026\/2027.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la Food and Drug Administration (FDA) am\u00e9ricaine pour ses mini-implants de cartilage issus de la bio-ing\u00e9nierie, les Cartibeads.<\/p>\n","protected":false},"author":6,"featured_media":29915,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1188,1181,1163,1141],"class_list":["post-29919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-healthcare-fr-2","tag-medical-devices-fr","tag-medtech-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vanarix obtient la d\u00e9signation Orphan Drug de la FDA | GGBa<\/title>\n<meta name=\"description\" content=\"Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la FDA am\u00e9ricaine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA | GGBa\" \/>\n<meta property=\"og:description\" content=\"Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la FDA am\u00e9ricaine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T10:23:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-07T10:30:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA pour ses Cartibeads\",\"datePublished\":\"2025-01-07T10:23:28+00:00\",\"dateModified\":\"2025-01-07T10:30:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\"},\"wordCount\":358,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"keywords\":[\"Healthcare\",\"Medical Devices\",\"Medtech\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\",\"name\":\"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"datePublished\":\"2025-01-07T10:23:28+00:00\",\"dateModified\":\"2025-01-07T10:30:48+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la FDA am\u00e9ricaine.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Les Cartibeads de Vanarix sont des mini-implants de cartilage issus de la bioing\u00e9nierie et con\u00e7us pour r\u00e9g\u00e9n\u00e9rer le cartilage endommag\u00e9, offrant ainsi une solution transformatrice pour les l\u00e9sions du cartilage articulaire. | \u00a9 Vanarix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA pour ses Cartibeads\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA | GGBa","description":"Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la FDA am\u00e9ricaine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/","og_locale":"fr_FR","og_type":"article","og_title":"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA | GGBa","og_description":"Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la FDA am\u00e9ricaine.","og_url":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-01-07T10:23:28+00:00","article_modified_time":"2025-01-07T10:30:48+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA pour ses Cartibeads","datePublished":"2025-01-07T10:23:28+00:00","dateModified":"2025-01-07T10:30:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/"},"wordCount":358,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","keywords":["Healthcare","Medical Devices","Medtech","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/","url":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/","name":"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","datePublished":"2025-01-07T10:23:28+00:00","dateModified":"2025-01-07T10:30:48+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Vanarix, une start-up du Biop\u00f4le sp\u00e9cialis\u00e9e dans la r\u00e9g\u00e9n\u00e9ration du cartilage, a re\u00e7u la d\u00e9signation Orphan Drug (ODD) de la FDA am\u00e9ricaine.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/01\/Vanarix-Cartibeads-1180x811-1.jpeg","width":1180,"height":811,"caption":"Les Cartibeads de Vanarix sont des mini-implants de cartilage issus de la bioing\u00e9nierie et con\u00e7us pour r\u00e9g\u00e9n\u00e9rer le cartilage endommag\u00e9, offrant ainsi une solution transformatrice pour les l\u00e9sions du cartilage articulaire. | \u00a9 Vanarix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/vanarix-obtient-la-designation-orphan-drug-de-la-fda-pour-ses-cartibeads\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Vanarix obtient la d\u00e9signation Orphan Drug de la FDA pour ses Cartibeads"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/29919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=29919"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/29919\/revisions"}],"predecessor-version":[{"id":29921,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/29919\/revisions\/29921"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/29915"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=29919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=29919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=29919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}